Hyperion
Therapeutics HPTX announced today that the results of the Phase
2 HALT-HE Study were presented at the Presidential Plenary Session I of the
63^rd Annual Meeting of the American Association for the Study of Liver
Diseases (AASLD) (The Liver Meeting®), in Boston, MA.
Principal Investigator Don Rockey, Chief of Medicine at the Medical University
of South Carolina delivered an oral presentation entitled, Randomized,
controlled, double-blind study of glycerol phenylbutyrate in patients with
cirrhosis and episodic hepatic encephalopathy.
Dr. Rockey explained, "The study results provide new insight into the
importance of ammonia in the pathogenesis of hepatic encephalopathy (HE).
Based on its safety profile, Hyperion's investigational drug, glycerol
phenylbutyrate (GPB), or "Ravicti", shows promise as a novel therapeutic
agent."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in